← Back to Analyst Consensus 
SLN N/A
Silence Therapeutics plc
Current Price —
Implied Upside —
Analysts 0
30-Day Momentum
▲ 0 upgrades / ▼ 1 downgrades / 0 reiterations from 1 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 21, 2026 | HC Wainwright & Co. | downgrade | Buy → Neutral | — | 44% |
| Aug 11, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Jun 24, 2026 | Cantor Fitzgerald | initiate | — → Overweight | — | 50% |
| Jun 17, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Mar 13, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Sep 16, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Aug 8, 2025 | Chardan Capital | maintain | Buy → Buy | $35 | 47% |
| Jun 13, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Jun 13, 2025 | Chardan Capital | maintain | Buy → Buy | $35 | 47% |
| May 9, 2025 | Goldman Sachs | maintain | Sell → Sell | $3 | 54% |
| May 9, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $25 | 54% |
| May 9, 2025 | Chardan Capital | maintain | Buy → Buy | $35 | 47% |
| Mar 7, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Mar 5, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $45 | 54% |
| Mar 4, 2025 | BMO Capital | maintain | Outperform → Outperform | $25 | 53% |
| Mar 4, 2025 | Goldman Sachs | maintain | Sell → Sell | $4 | 54% |
| Feb 11, 2025 | Goldman Sachs | initiate | — → Sell | $6 | 54% |
| Feb 3, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Jan 29, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Dec 10, 2024 | Chardan Capital | maintain | Buy → Buy | $55 | 47% |
| Dec 9, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Nov 20, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Nov 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Nov 14, 2024 | Chardan Capital | maintain | Buy → Buy | $55 | 47% |
| Oct 8, 2024 | Morgan Stanley | reiterate | Overweight → Overweight | $49 | 54% |
| Aug 30, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Aug 16, 2024 | Chardan Capital | maintain | Buy → Buy | $55 | 47% |
| Jun 28, 2024 | Morgan Stanley | maintain | Overweight → Overweight | $49 | 54% |
| Jun 28, 2024 | Chardan Capital | maintain | Buy → Buy | $55 | 47% |
| Jun 27, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Jun 20, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| May 31, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| May 24, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| May 17, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| May 17, 2024 | Chardan Capital | maintain | Buy → Buy | $42 | 47% |
| Apr 22, 2024 | Morgan Stanley | maintain | Overweight → Overweight | $45 | 54% |
| Mar 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Mar 14, 2024 | Morgan Stanley | maintain | Overweight → Overweight | $45 | 54% |
| Mar 14, 2024 | Chardan Capital | maintain | Buy → Buy | $42 | 47% |
| Mar 13, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $75 | 44% |
| Feb 22, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Jan 31, 2024 | BMO Capital | initiate | — → Outperform | $67 | 53% |
| Jan 18, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Nov 17, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $75 | 44% |
| Aug 17, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $80 | 44% |
| Aug 17, 2023 | Chardan Capital | reiterate | Buy → Buy | $26 | 47% |
| Jul 24, 2023 | Morgan Stanley | reiterate | Overweight → Overweight | $20 | 54% |
| Jul 17, 2023 | Morgan Stanley | reiterate | Overweight → Overweight | $20 | 54% |
| Jun 26, 2023 | Morgan Stanley | reiterate | Overweight → Overweight | $20 | 54% |
| Jun 20, 2023 | Morgan Stanley | reiterate | — → Overweight | $20 | 54% |
Price Target Trend
Apr 22, 2026 Oct 26, 2026
EPS Estimates
0q —
+1y —
+1q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days